Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.
- As is typical of late-stage clinical trials, such women will not be enrolled in Corcepts upcoming Phase 3 trial.
- In this large, randomized study, women with recurrent, platinum-resistant ovarian cancer who were administered relacorilant at the time they received nab-paclitaxel exhibited meaningful improvements in progression free survival, duration of response and overall survival without increased side effects compared to women who received nab-paclitaxel alone.
- No approved therapy has been shown to significantly extend survival compared to standard chemotherapy in women with platinum-resistant ovarian cancer.
- Fourteen additional women in the intermittent arm and nine additional women in the comparator arm are expected to contribute to the final overall survival results.